189 related articles for article (PubMed ID: 15093697)
21. Brain nuclear factor kappa B is involved in the corticotropin-releasing factor-induced central activation of sympatho-adrenomedullary outflow in rats.
Okada S; Yamaguchi-Shima N; Shimizu T; Arai J; Yorimitsu M; Yokotani K
Eur J Pharmacol; 2008 Apr; 584(1):207-12. PubMed ID: 18304530
[TBL] [Abstract][Full Text] [Related]
22. Corticotropin-releasing factor (CRF) and the urocortins differentially regulate catecholamine secretion in human and rat adrenals, in a CRF receptor type-specific manner.
Dermitzaki E; Tsatsanis C; Minas V; Chatzaki E; Charalampopoulos I; Venihaki M; Androulidaki A; Lambropoulou M; Spiess J; Michalodimitrakis E; Gravanis A; Margioris AN
Endocrinology; 2007 Apr; 148(4):1524-38. PubMed ID: 17194738
[TBL] [Abstract][Full Text] [Related]
23. Physiological roles of urocortins, human homologues of fish urotensin I, and their receptors.
Suda T; Kageyama K; Sakihara S; Nigawara T
Peptides; 2004 Oct; 25(10):1689-701. PubMed ID: 15476936
[TBL] [Abstract][Full Text] [Related]
24. Mediation of burn-induced hypermetabolism by CRF receptor-2 activity.
Chance WT; Dayal R; Friend LA; Thomas I; Sheriff S
Life Sci; 2007 Feb; 80(11):1064-72. PubMed ID: 17222429
[TBL] [Abstract][Full Text] [Related]
25. Regional hemodynamic actions of selective corticotropin-releasing factor type 2 receptor ligands in conscious rats.
Gardiner SM; March JE; Kemp PA; Davenport AP; Wiley KE; Bennett T
J Pharmacol Exp Ther; 2005 Jan; 312(1):53-60. PubMed ID: 15328375
[TBL] [Abstract][Full Text] [Related]
26. Involvement of the corticotropin-releasing factor (CRF) type 2 receptor in CRF-induced thyrotropin release by the amphibian pituitary gland.
Okada R; Miller MF; Yamamoto K; De Groef B; Denver RJ; Kikuyama S
Gen Comp Endocrinol; 2007 Feb; 150(3):437-44. PubMed ID: 17188689
[TBL] [Abstract][Full Text] [Related]
27. Peripheral and central administration of exogenous urocortin 1 disrupts the fasted motility pattern of the small intestine in rats via the corticotrophin releasing factor receptor 2 and a cholinergic mechanism.
Yin Y; Dong L; Yin D
J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 2):e79-87. PubMed ID: 17944898
[TBL] [Abstract][Full Text] [Related]
28. The roles of corticotropin-releasing factor-related peptides and their receptors in the cardiovascular system.
Nazarloo HP; Buttrick PM; Saadat H; Dunn AJ
Curr Protein Pept Sci; 2006 Jun; 7(3):229-39. PubMed ID: 16787262
[TBL] [Abstract][Full Text] [Related]
29. Intracerebroventricularly administered urocortin inhibits gastric emptying in mice.
Nagata T; Uemoto M; Yuzuriha H; Asakawa A; Inui A; Fujimiya M; Sakamaki R; Kasuga M; Shinfuku N
Int J Mol Med; 2005 Jun; 15(6):1041-3. PubMed ID: 15870911
[TBL] [Abstract][Full Text] [Related]
30. Human urocortin 2, a corticotropin-releasing factor (CRF)2 agonist, and ovine CRF, a CRF1 agonist, differentially alter feeding and motor activity.
Zorrilla EP; Reinhardt LE; Valdez GR; Inoue K; Rivier JE; Vale WW; Koob GF
J Pharmacol Exp Ther; 2004 Sep; 310(3):1027-34. PubMed ID: 15115804
[TBL] [Abstract][Full Text] [Related]
31. Extrapituitary effects of corticotropin-releasing factor.
Lenz HJ
Horm Metab Res Suppl; 1987; 16():17-23. PubMed ID: 3327796
[TBL] [Abstract][Full Text] [Related]
32. Regulation of corticotropin-releasing factor and its types 1 and 2 receptors by leptin in rats subjected to treadmill running-induced stress.
Huang Q; Timofeeva E; Richard D
J Endocrinol; 2006 Oct; 191(1):179-88. PubMed ID: 17065401
[TBL] [Abstract][Full Text] [Related]
33. Localization and physiological roles of urocortin.
Oki Y; Sasano H
Peptides; 2004 Oct; 25(10):1745-9. PubMed ID: 15476941
[TBL] [Abstract][Full Text] [Related]
34. Impaired passive avoidance acquisition in Wistar rats after restraint/cold stress and/or stresscopin administration.
Klenerová V; Kaminský O; Sída P; Hlinák Z; Krejcí I; Hynie S
Gen Physiol Biophys; 2003 Mar; 22(1):115-20. PubMed ID: 12870706
[TBL] [Abstract][Full Text] [Related]
35. Urocortin 2 acts centrally to delay gastric emptying through sympathetic pathways while CRF and urocortin 1 inhibitory actions are vagal dependent in rats.
Czimmer J; Million M; Taché Y
Am J Physiol Gastrointest Liver Physiol; 2006 Mar; 290(3):G511-8. PubMed ID: 16223946
[TBL] [Abstract][Full Text] [Related]
36. In vivo evidence for ligand-specific receptor activation in the central CRF system, as measured by local cerebral glucose utilization.
Warnock G; Moechars D; Langlois X; Steckler T
Peptides; 2009 May; 30(5):947-54. PubMed ID: 19428773
[TBL] [Abstract][Full Text] [Related]
37. The effects of centrally administered dexmedetomidine on cardiovascular and sympathetic function in conscious rats.
Shirasaka T; Qiu DL; Kannan H; Takasaki M
Anesth Analg; 2007 Dec; 105(6):1722-8, table of contents. PubMed ID: 18042874
[TBL] [Abstract][Full Text] [Related]
38. Cardiovascular effects of centrally administered arachidonic acid in haemorrhage-induced hypotensive rats: investigation of a peripheral mechanism.
Yalcin M; Aydin C
Clin Exp Pharmacol Physiol; 2009 Apr; 36(4):447-53. PubMed ID: 19702598
[TBL] [Abstract][Full Text] [Related]
39. Autonomic and cardiovascular effects of corticotropin-releasing factor in the spontaneously hypertensive rat.
Brown MR; Hauger R; Fisher LA
Brain Res; 1988 Feb; 441(1-2):33-40. PubMed ID: 2834002
[TBL] [Abstract][Full Text] [Related]
40. Corticotropin-releasing factor receptor type 1, but not type 2, in the ventromedial hypothalamus modulates dopamine release in female rats.
Muramatsu T; Inoue K; Iwasaki S; Yamauchi T; Hayashi T; Kiriike N
Pharmacol Biochem Behav; 2006 Oct; 85(2):435-40. PubMed ID: 17109941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
